Brief: Chromadex Q2 Sales $16.7 Million

Niagen Bioscience

10/08/2022 21:59

Chromadex Corp  CDXC.O :
    * ORATION REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
    * Q2 LOSS PER SHARE $0.09
    * Q2 SALES $16.7 MILLION
    * Q2 EARNINGS PER SHARE VIEW $-0.09, REVENUE VIEW $18.6
MILLION --
REFINITIV IBES DATA
    * QTRLY FOR FULL YEAR, COMPANY EXPECTS HIGH SINGLE DIGIT
REVENUE
GROWTH
    * EXPECTS TO APPROACH CASH FLOW BREAK-EVEN IN Q3 AND BE CASH
FLOW
BREAK-EVEN OR BETTER IN Q4 OF 2022

Source text for Eikon:  ID:nBw3LJYvYa 
Further company coverage:  CDXC.O